Vanguard Global Advisers
LTRN icon

Vanguard Global Advisers’s Lantern Pharma LTRN Stock Holding History

Vanguard Global Advisers’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.82K Hold
2,355
– – ﹤0.01% 3479
2026
Q1 		$3.23K Buy
+2,355
New +$6.58K ﹤0.01% 3591

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Vanguard Global Advisers's LTRN Position: Q2 2026 in Review

Vanguard Global Advisers held its Lantern Pharma (LTRN) position steady in Q2 2026 at 2,355 shares worth $9.82K. The position accounts for ﹤0.01% of the portfolio, ranked #3479.

Vanguard Global Advisers first reported a position in LTRN in Q1 2026 and has held it in 2 quarters since. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Vanguard Global Advisers held 2,355 shares of Lantern Pharma worth $9.82K as of Q2 2026.
  • Vanguard Global Advisers left its Lantern Pharma share count unchanged in Q2 2026.
  • Lantern Pharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3479 holding.
  • Vanguard Global Advisers first reported a position in Lantern Pharma in Q1 2026 and has held it in 2 quarters since.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.